Intellia Therapeutics, Inc (NTLA) Dividend History

Company News

• Analysts Think These Stocks Could More Than Double in Value

  Analysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.

  Investing.com

  Featured Companies: NVAX SEPN
• INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  Bragar Eagel & Squire, P.C. is investigating potential claims against Intellia Therapeutics, Inc. on behalf of long-term stockholders following a class action complaint. The complaint alleges that Intellia failed to disclose material information about the declining demand for its NTLA-3001 program, leading to its discontinuation and a drop in the company's stock price.

  GlobeNewswire Inc.
• Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

  Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. The data showed deep, durable and consistent reductions in serum TTR levels, as well as clinically meaningful improvements in related outcomes.

  GlobeNewswire Inc.
• Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

  The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

  GlobeNewswire Inc.

  Featured Companies: ATXS CAMP IONS KALV
• Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

  The article discusses the upcoming earnings reports of AMD and Shopify, which are expected to show strong revenue and earnings growth. It also mentions Cathie Wood's recent purchases of AMD, Shopify, and Intellia Therapeutics, and provides an analysis of the companies' prospects.

  The Motley Fool

  Featured Companies: AMD SHOP